203 related articles for article (PubMed ID: 37165926)
1. Anti-PD-1 monoclonal antibody-resistant esophageal squamous cell carcinoma showing the abscopal effect: A case report with T-cell receptor/B-cell receptor repertoire analysis.
Takehara Y; Mimura K; Suzuki Y; Watanabe Y; Yoshimoto Y; Saze Z; Sato H; Tamaki T; Kono K
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1832. PubMed ID: 37165926
[TBL] [Abstract][Full Text] [Related]
2. The abscopal effect in head-and-neck squamous cell carcinoma treated with radiotherapy and nivolumab: a case report and literature review.
Forner D; Horwich P; Trites JR; Hollenhorst H; Bullock M; Lamond NWD
Curr Oncol; 2020 Dec; 27(6):330-335. PubMed ID: 33380865
[TBL] [Abstract][Full Text] [Related]
3. Abscopal effect of radiation on lymph node metastasis in esophageal carcinoma: A case report and literature review.
Zhao X; Kang J; Zhao R
Oncol Lett; 2018 Sep; 16(3):3555-3560. PubMed ID: 30127961
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
5. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
6. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
7. [An Abscopal Effect after Palliative Radiotherapy in a Patient with a Locally and Lymph Node Recurrent Gastric Cancer].
Nakajima T; Kuwabara K; Shimanuki K; Inoue N; Kono K
Gan To Kagaku Ryoho; 2023 Mar; 50(3):399-400. PubMed ID: 36927922
[TBL] [Abstract][Full Text] [Related]
8. Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice.
Li M; Zhang X; Zhao F; Luo Y; Kong L; Yu J
Radiat Oncol; 2016 Feb; 11():18. PubMed ID: 26846932
[TBL] [Abstract][Full Text] [Related]
9. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y
Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Ishikawa Y; Suzuki M; Yamaguchi H; Seto I; Machida M; Takagawa Y; Jingu K; Kikuchi Y; Murakami M
J Med Case Rep; 2022 Feb; 16(1):68. PubMed ID: 35152904
[TBL] [Abstract][Full Text] [Related]
11. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
12. Overcoming immune-resistance in laryngeal cancer: a case report of the abscopal effect and nivolumab beyond progression.
Marco F; Gianluca A; Mariagrazia T; Luca EP
Immunotherapy; 2022 Oct; 14(14):1089-1095. PubMed ID: 36040238
[TBL] [Abstract][Full Text] [Related]
13. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report.
Hori K; Hirohashi Y; Aoyagi T; Taniguchi N; Murakumo M; Miyata H; Torigoe T; Abe T; Shinohara N; Morita K
Exp Ther Med; 2020 Mar; 19(3):1903-1907. PubMed ID: 32104247
[TBL] [Abstract][Full Text] [Related]
14. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.
Li J; Zhao Z; Du G; Dai T; Zhen X; Cai H; Liao D; Xiang M; Wen Y; Geng L; Yang X; Feng G; Zhang Y; Bai J; Liu L; Du X
Medicine (Baltimore); 2019 Jun; 98(26):e16176. PubMed ID: 31261551
[TBL] [Abstract][Full Text] [Related]
16. Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report.
Endo M; Fukuda Y; Okada K; Ogawa K; Nakamura M; Takahashi S; Kawahara M; Akahane K; Nagai Y; Yamaguchi H; Nishino H; Mori H; Shirai K
Case Rep Oncol; 2023; 16(1):1345-1352. PubMed ID: 37946746
[TBL] [Abstract][Full Text] [Related]
17. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
18. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
